SCHEMBL6472980

SCHEMBL6472980

CCC(=O)c1ccc(-c2cc(NCc3ccc(COC(=O)c4ccccc4)c(COC(=O)c4ccccc4)c3)ccc2C)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.42
GAA P10253 3/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 6/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
NPC1 O15118 4/20 0.41
HSP90AA1 P07900 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
SENP1 Q9P0U3 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MAPK1 P28482 1/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2877573 0.92 RAB9A (0.42) RAB9AGAAKMT2AMAPTALDH1A1
SCHEMBL2858744 0.82 VDR (0.38) RAB9AKMT2AMAPTALDH1A1MEN1
SCHEMBL6473768 0.77 MAPT (0.34) RAB9AGAAKMT2AMAPTALDH1A1
SCHEMBL2851878 0.76 RAB9A (0.44) RAB9AGAAKMT2AMAPTALDH1A1
SCHEMBL6886884 0.75 MRGPRX4 (0.43) RAB9AGAAKMT2AMAPTALDH1A1
SCHEMBL2858749 0.75 MAPT (0.36) RAB9AGAAKMT2AMAPTALDH1A1
SCHEMBL6566321 0.75 MRGPRX4 (0.48) RAB9AALDH1A1L3MBTL1SMN1; SMN2PPARA
SCHEMBL2856205 0.71 ALDH1A1 (0.45) RAB9AKMT2AMAPTALDH1A1MEN1
SCHEMBL2852532 0.70 SMN1; SMN2 (0.48) RAB9AGAAKMT2AMAPTALDH1A1
SCHEMBL2872936 0.70 RAB9A (0.33) RAB9AGAAKMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR RAB9A 3535/4885GAA 802/4885KMT2A 4353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.